Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease☆
Section snippets
Design and patient population
This was a multicenter, randomized, double-blind, placebo-controlled trial in children with CHD. The study was conducted during 4 consecutive RSV seasons, 1998 through 2002. Each child participated during only one season. The local institutional review board or independent ethics committee approved the study protocol, and parents or guardians gave written informed consent before participation. The study was conducted at 76 centers in the United States (n = 47), Canada (n = 6), Sweden (n = 3), Germany
Results
Starting on November 1 and ending on or before December 31 of each year between 1998 and 2001, a total of 1287 patients were randomly assigned. Study sites in the United States and Canada randomly assigned 800 (62.2%) and 133 (10.3%) children, respectively. The remaining children were randomly assigned in Poland (150, 11.6%), the United Kingdom (95, 7.4%), Germany (49, 3.8%), Sweden (33, 2.6%), and France (27, 2.1%). From 1 to 45 patients were randomly assigned per site, with an average of 17
Discussion
This large, placebo-controlled trial demonstrates the benefit of palivizumab prophylaxis in children with CHD. Children receiving prophylaxis had a 45% (95% CI: 23, 67) relative reduction in RSV hospitalization. These results are consistent with the IMpact-RSV trial in children with prematurity with or without chronic lung disease, in which a 55% (95% CI: 38, 72) relative reduction was observed.14 The reduction in RSV hospitalization rate was evident in both the cyanotic (7.9% placebo vs 5.6%
Acknowledgements
We thank W. Ripley Ballou, MD, James F. Balsley, MD, PhD, Bernard Landry, MPH, Judith Scott, MPH, Peggy McDonald, RN, Lori Ovington, Ray Hsieh, Rong Ye, and Kevin Crawford of MedImmune, Inc, for their contributions to this study; Barbara Shepherd, PhD, of MedImmune, Inc, for assistance in preparation of the manuscript; Virginia Capps, Randi Gower, Patricia Keegan, and the clinical monitoring and data management/biostatistics staff at PPD Development, Inc; the clinical research staff at all the
References (18)
- et al.
Risk factors for severe respiratory syncytial virus infection in infants
Respir Med
(2002) - et al.
Rates of hospitalization for respiratory syncytial virus among children in Medicaid
J Pediatr
(2000) - et al.
Pediatric Investigators Collaborative Network on Infections in Canada: improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children
J Pediatr
(1992) - et al.
Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease
J Pediatr
(1998) - et al.
Bronchiolitis-associated hospitalizations among US children
JAMA
(1999) - et al.
Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997
J Infect Dis
(2001) - et al.
Mortality associated with influenza and respiratory syncytial virus in the United States
JAMA
(2003) - et al.
Respiratory syncytial viral infection in infants with congenital heart disease
N Engl J Med
(1982) - et al.
Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience
Crit Care Med
(1992)
Cited by (0)
- ☆
Supported by MedImmune, Inc.
- ∗
The members of the Cardiac Synagis Study Group appear in the Appendix.